All Metrics
RMD Valuation Metrics
RMD Stock Price Metrics
RMD Dividend Metrics
RMD Growth Rate Metrics
RMD Discounted Cash Flow Metrics
| Fair Value Price | $313.47 |
| Margin of Safety | 57.84% |
RMD Revenue Metrics
RMD PE Ratio Metrics
| PE Ratio | 19.21 |
| PE Ratio Avg TTM | 25.43 |
| PE Ratio Avg 3Y | 28.42 |
| Current VS TTM Avg | -24.46% |
| Current VS 3Y Avg | -32.40% |
| Current VS 5Y Avg | -39.60% |
RMD PS Ratio Metrics
| PS Ratio | 5.27 |
| PS Ratio Avg TTM | 6.91 |
| PS Ratio Avg 3Y | 6.72 |
| Current VS TTM Avg | -23.75% |
| Current VS 3Y Avg | -21.57% |
| Current VS 5Y Avg | -32.50% |
RMD PB Ratio Metrics
| PB Ratio | 4.50 |
| PB Ratio Avg TTM | 5.97 |
| PB Ratio Avg 3Y | 6.30 |
| Current VS TTM Avg | -24.66% |
| Current VS 3Y Avg | -28.56% |
| Current VS 5Y Avg | -43.10% |
RMD Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 16.70 |
| PFCF Ratio Avg TTM | 21.26 |
| PFCF Ratio Avg 3Y | 25.24 |
| Current VS TTM Avg | -21.45% |
| Current VS 3Y Avg | -33.83% |
| Current VS 5Y Avg | -69.96% |
RMD Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.13 |
| Debt/Equity Ratio Avg TTM | 0.14 |
| Debt/Equity Ratio Avg 3Y | 0.23 |
| Current VS TTM Avg | -9.90% |
| Current VS 3Y Avg | -42.95% |
| Current VS 5Y Avg | -49.97% |
RMD PEG Ratio Metrics
| PEG Ratio | 0.72 |
| PEG Ratio Avg TTM | 1.36 |
| PEG Ratio Avg 3Y | 1.45 |
| Current VS TTM Avg | -47.25% |
| Current VS 3Y Avg | -50.26% |
| Current VS 5Y Avg | -45.78% |
RMD FCF Yield
| FCF Yield | 5.99% |
| FCF Yield Avg TTM | 4.80% |
| FCF Yield Avg 3Y | 3.92% |
| Current VS TTM Avg | +24.88% |
| Current VS 3Y Avg | +52.82% |
| Current VS 5Y Avg | +115.75% |
RMD Earnings Yield
| Earnings Yield | 5.21% |
| Earnings Yield Avg TTM | 4.02% |
| Earnings Yield Avg 3Y | 3.54% |
| Current VS TTM Avg | +29.63% |
| Current VS 3Y Avg | +46.99% |
| Current VS 5Y Avg | +76.79% |
RMD EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 14.95 |
| Ev/Ebit Ratio Avg TTM | 20.57 |
| Ev/Ebit Ratio Avg 3Y | 23.07 |
| Current VS TTM Avg | -27.33% |
| Current VS 3Y Avg | -35.19% |
| Current VS 5Y Avg | -47.07% |
RMD EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 12.99 |
| Ev/Ebitda Ratio Avg TTM | 18.17 |
| Ev/Ebitda Ratio Avg 3Y | 20.02 |
| Current VS TTM Avg | -28.50% |
| Current VS 3Y Avg | -35.12% |
| Current VS 5Y Avg | -45.89% |
RMD EV/Assets Ratio Metrics
| Ev/Assets Ratio | 3.23 |
| Ev/Assets Ratio Avg TTM | 4.34 |
| Ev/Assets Ratio Avg 3Y | 4.44 |
| Current VS TTM Avg | -25.65% |
| Current VS 3Y Avg | -27.26% |
| Current VS 5Y Avg | -40.42% |
RMD EV/Sales Ratio Metrics
| Ev/Sales Ratio | 5.13 |
| Ev/Sales Ratio Avg TTM | 6.83 |
| Ev/Sales Ratio Avg 3Y | 6.82 |
| Current VS TTM Avg | -24.85% |
| Current VS 3Y Avg | -24.73% |
| Current VS 5Y Avg | -35.66% |
RMD Current Ratio Metrics
| Current Ratio | 3.01 |
| Current Ratio Avg TTM | 3.16 |
| Current Ratio Avg 3Y | 3.02 |
| Current VS TTM Avg | -4.86% |
| Current VS 3Y Avg | -0.52% |
| Current VS 5Y Avg | +1.18% |
RMD Quick Ratio Metrics
| Quick Ratio | 2.33 |
| Quick Ratio Avg TTM | 2.36 |
| Quick Ratio Avg 3Y | 2.05 |
| Current VS TTM Avg | -1.25% |
| Current VS 3Y Avg | +14.04% |
| Current VS 5Y Avg | +25.62% |
RMD ROIC Metrics
| ROIC | 19.56% |
| ROIC Avg 3Y | 17.73% |
| ROIC Avg 5Y | 16.77% |
| Current VS 3Y Avg | +10.31% |
| Current VS 5Y Avg | +16.64% |
| Current VS 10Y Avg | +29.33% |
RMD Return on Assets Metrics
| ROA | 17.14% |
| ROA Avg TTM | 16.00% |
| ROA Avg 3Y | 15.15% |
| Current VS TTM Avg | +7.13% |
| Current VS 3Y Avg | +13.15% |
| Current VS 5Y Avg | +22.17% |
RMD Return on Equity Metrics
| ROE | 23.47% |
| ROE Avg TTM | 22.23% |
| ROE Avg 3Y | 22.34% |
| Current VS TTM Avg | +5.58% |
| Current VS 3Y Avg | +5.03% |
| Current VS 5Y Avg | +7.73% |
RMD Net Profit Margin Metrics
| Net Profit Margin | 27.86% |
| Net Profit Margin Avg TTM | 27.59% |
| Net Profit Margin Avg 3Y | 24.49% |
| Current VS TTM Avg | +0.95% |
| Current VS 3Y Avg | +13.73% |
| Current VS 5Y Avg | +18.11% |
Last Updated: Friday, June 26, 2026
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell